2022 World Conference on Lung Cancer (ePosters)-EP08.02-127. Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

EP08.02-127. Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

Back to course

Pdf Summary

This study aimed to investigate the resistance mechanisms to osimertinib in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Tissue samples were collected from patients who developed resistance to osimertinib and were analyzed using the FoundationOne CDx assay. The study found that potentially druggable genetic alterations, such as MET amplification, EGFR C797S, and EGFR L718V/Q, took longer to develop compared to other resistance mechanisms. Activating EGFR mutations were detected in most patients, along with T790M and TP53 mutations. The time from the start of osimertinib therapy to tumor re-biopsy was longer in patients with potentially druggable genetic alterations. Histology changes were also observed in some patients. Overall, the study provides valuable insights into the resistance mechanisms to osimertinib in EGFR-mutated NSCLC.<br /><br />Osimertinib is recommended as the first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation. It is also effective in patients with acquired T790M mutations. The study utilized next-generation sequencing to identify possible mechanisms of resistance in tumor tissues that developed resistance to osimertinib. The findings of this study contribute to our understanding of resistance mechanisms and can potentially guide treatment strategies for patients with EGFR-mutated NSCLC who experience resistance to osimertinib. Further research is necessary to validate these findings and explore potential therapeutic approaches targeting the identified resistance mechanisms.

Asset Subtitle

Bin-Chi Liao

Meta Tag

Speaker Bin-Chi Liao

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

resistance mechanisms

osimertinib

NSCLC

EGFR mutations

FoundationOne CDx assay

MET amplification

EGFR C797S

EGFR L718V/Q

T790M

tumor re-biopsy